Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 134,986 251,929 319,053 656,089
Total Sell Value $11,097,511 $21,508,551 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 9 19 27 56
End Date 2024-04-04 2024-01-02 2023-07-04 2022-07-04

   
Records found: 1285
  Page 38 of 52  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-01-11 4 AS $89.84 $359,360 D/D (4,000) 170,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-01-11 4 OE $17.33 $69,320 D/D 4,000 174,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-01-10 4 AS $91.31 $365,240 D/D (4,000) 170,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-01-10 4 OE $17.33 $69,320 D/D 4,000 174,682     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2017-01-09 4 AS $90.00 $450,000 D/D (5,000) 18,100     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-01-09 4 AS $89.79 $359,160 D/D (4,000) 170,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-01-09 4 OE $17.33 $69,320 D/D 4,000 174,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-01-06 4 AS $87.19 $348,760 D/D (4,000) 170,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-01-06 4 OE $17.33 $69,320 D/D 4,000 174,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-12-30 4 AS $83.35 $333,400 D/D (4,000) 170,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-12-30 4 OE $17.33 $69,320 D/D 4,000 174,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-12-29 4 AS $83.84 $335,360 D/D (4,000) 170,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-12-29 4 OE $17.33 $69,320 D/D 4,000 174,682     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2016-11-25 4 AS $87.40 $1,310,988 D/D (15,000) 113,878     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2016-11-25 4 OE $26.49 $397,350 D/D 15,000 128,878     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-11-22 4 AS $85.69 $5,976,515 D/D (69,743) 170,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-11-22 4 OE $26.49 $1,847,492 D/D 69,743 240,425     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-11-21 4 AS $87.56 $6,106,478 D/D (69,744) 170,682     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-11-21 4 OE $26.49 $1,847,519 D/D 69,744 240,426     -
   Davis George Eric EVP, General Counsel   •       –      –    2016-11-18 4 AS $90.42 $452,100 D/D (5,000) 70,798     -
   Davis George Eric EVP, General Counsel   •       –      –    2016-11-18 4 OE $38.59 $192,950 D/D 5,000 75,798     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-11-16 4 AS $90.97 $3,790,795 D/D (41,670) 323,368     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2016-11-16 4 OE $17.54 $730,892 D/D 41,670 365,038     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2016-11-09 4 S $90.61 $1,812,206 D/D (20,000) 23,100     -
   Lawlis V Bryan Director   –       •      –    2016-11-09 4 AS $95.00 $712,500 D/D (7,500) 13,860     -
  1285 Records found
  Previous  30  31  32  33  34  35  36  37  38  39  Next   
  Page 38 of 52
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us